Short answer
Azenta, Inc. (AZTA) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Azenta UK Ltd. acquired UK Biocentre Limited for GBP 20.5M net of cash, closed March 4, 2026.
Azenta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Azenta UK Ltd. acquired UK Biocentre Limited for GBP 20.5M net of cash, closed March 4, 2026
- Up to GBP 1.8M in contingent consideration tied to milestone achievements
- UK Biocentre is a UK-based sample management, storage, and high-throughput processing services provider
- Post-acquisition, UK Biocentre becomes Azenta's European hub for its Sample Repository Services (SRS) segment
Item 7.01 · Regulation FD Disclosure
- Azenta (AZTA) entered a Share Purchase Agreement, announced via press release March 4, 2026
- Reg FD disclosure signals material transaction: Share Purchase Agreements typically involve significant asset or equity stake sales/acquisitions
- Full deal terms, counterparty identity, and financial impact require review of the accompanying press release exhibit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Azenta, Inc. 8-K filings
Get the next AZTA 8-K as it lands
Follow AZTA for push alerts, or ask the research agent what this filing means.